• About us
• Contact

Advertisement

Organisation › Details

Mologen (Group)

MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase. The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200). *

 

	Start	1997-01-01 existent
	End	2019-12-03 bankruptcy filed
	Industry	BIOTECH
	Industry 2	MIDGE® technology (Mologen)
	Person	Manth, Stefan M. (Mologen 201904– CEO prior Supervisory Board + SAB Member before Roche for 20 years
	Person 2	Miller, Walter (Mologen 201604– CFO before Nuvisan Gmbh + Santhera Pharmaceuticals)
	Region	Berlin
	Country	Germany
	Street	30 Fabeckstr.
	City	14195 Berlin
	Tel	+49-30-841788-0
		Address record changed: 2020-12-02
Basic data	Employees	C: 51 to 100 (2017-12-31)
	Currency	EUR
	Annual sales	47,000 (revenues (2017) 2017-12-31)
	Profit	-19,281,000 (2017-12-31)
	Cash	8,061,000 (2017-12-31)
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for Mologen (Group)

• [1] Mologen AG. (12/3/19). "Press Release: Insolvency Filing [Not for publication or distribution in or into US, AU, CA or JP or any jurisdiction in which unlawful]". Berlin....
• [2] Mologen AG. (8/5/19). "Press Release: Mologen AG Announces Top Line Data of Pivotal IMPALA Study in Metastatic Colorectal Cancer. Primary Endpoint Not Met". Berlin....
• [3] Mologen AG. (3/27/19). "Press Release: Top Pharma Manager Stefan M. Manth, MD, to Become CEO of Mologen AG". Berlin....
• [4] Mologen AG. (3/18/19). "Press Release: Early Departure of CEO". Berlin....
• [5] Mologen AG. (1/17/19). "Press Release: Full Placement of Convertible Bond 2019/2027. Total Amount Issued: EUR2.7 Million, Maturity of 8 Years, Coupon of 6% p.a. [NOT FOR US, CA, JP, et al.]". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.